DR. STEVEN L REED, M.D.
Medical Practice at 120 Ave, Kirkland, WA

8429099, Apr 23, 2013

Oct 14, 2010

12/904957

Michael Perkowitz - Seattle WA, US
Kevin Francis Eustice - Seattle WA, US
Steven M. Reed - Seattle WA, US
Jonathan D. Lazarus - Mercer Island WA, US
Kenneth Dwight Krossa - Kirkland WA, US

ARO, Inc. - Seattle WA

G06F 15/18, G06F 7/00

706 12, 707705

An entity recognition model is trained to use gazetteers to recognize entities referenced in documents. When a document associated with a user is received for recognizing entities referenced therein, a gazetteer is selected based on user contexts associated with the user. The document is analyzed using the gazetteer according to the entity recognition model to recognize an entity referenced therein. Additional facts associated with the recognized entities and actions applicable to the recognized entities are provided to enable the user to perform the applicable actions against the recognized entity.

6660840, Dec 9, 2003

Sep 17, 1999

09/398169

Steven G. Reed - Seattle WA

Corixa Corporation - Seattle WA

C07K 100

530350, 530300, 4241841, 4242351, 4242341, 4242651, 4242691, 930210

Methods for eliciting or enhancing immune responses to antigens, including tumor antigens, and/or DNA vaccines are provided. The methods employ polypeptides or nucleic acid compositions that contain at least a biologically active portion of a or homologue of the eukaryotic initiation factor 4A, or a variant thereof. Such polypeptides and compositions are useful for enhancing or eliciting a patients cellular and/or humoral immune response, for instance within methods for treating tumors.

7695925, Apr 13, 2010

Nov 2, 2006

12/092562

Raymond L. Houghton - Seattle WA, US
Steven G. Reed - Seattle WA, US
Syamal Raychaudhuri - Seattle WA, US

Inbios International, Inc. - Seattle WA
Infectious Disease Research Institute - Seattle WA

G01N 33/53

435 722, 435 71, 435 772, 435975, 4242691, 4241851, 4241921, 530350

Compositions comprising fusion polypeptides of epitopes are provided, together with methods for the use of such compositions in the diagnosis of infection and in screening blood supplies. Diagnostic kits comprising such compositions are also provided.

8173383, May 8, 2012

Jan 24, 2011

13/012398

Raymond L. Houghton - Seattle WA, US
Steven G. Reed - Seattle WA, US
Syamal Raychaudhuri - Seattle WA, US

InBios International, Inc. - Seattle WA

G01N 33/53, G01N 33/542, G01N 33/00, A61K 39/00, C07K 1/00, C07K 14/00, C07K 17/00

435 794, 435 79, 435 792, 435 71, 4241841, 4241851, 4242651, 4242691, 530350

The present invention provides rapid diagnostic assays for the detection of which can readily be used in the field, leading to more rapid treatment. In certain embodiments, the inventive assays, including ELISA and lateral flow assays, employ antibodies that may be effectively employed to detect the antigen TSA, which is present in both promastigotes grown in culture and in amastigotes. Such assays may be employed to detect the presence of cutaneous leishmaniasis in a subject using scrapings, biopsies, and/or aspirates taken from cutaneous lesions.

8470338, Jun 25, 2013

Apr 27, 2006

11/912730

Rhea Coler - Seattle WA, US
Yves Lobet - Rixensart, BE
Steven Reed - Seattle WA, US

GlaxoSmithKline Biologicals, S.A. - Rixensart
Infectious Disease Research Institute - Seattle WA

A61K 39/04, A61K 49/00, A61K 39/02

4242481, 424 91, 424 92, 4242341, 536 231, 536 237

The present invention is directed to methods of preventing reactivation of active and latent infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a infection.

2014005, Feb 20, 2014

May 16, 2013

13/895574

- Rixensart, BE
Steven Reed - Seattle WA, US

INFECTIOUS DISEASE RESEARCH INSTITUTE - Seattle WA
GLAXOSMITHKLINE BIOLOGICALS SA - Rixensart

C07K 14/35, A61K 31/4409, A61K 31/496, A61K 39/04

424450, 4241901

The present invention is directed to methods of preventing reactivation of active and latent infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a infection.

2010017, Jul 8, 2010

Oct 3, 2007

12/442538

Mark Alderson - Bainbridge WA, US
Rhea Coler - Seattle WA, US
Yves Lobet - Rixensart, BE
Jean-Francois L. Maisonneuve - Federal Way WA, US
Pascal Mettens - Rixensart, BE
Peter Probst - Seattle WA, US
Steven Reed - Seattle WA, US

A61K 39/118, A61P 31/04, A61P 27/00, C07K 14/295

4241901, 530350

Methods and compositions for the treatment or prevention of ocular infection. Compositions comprise one or more proteins, immunogenic fragments thereof or polynucleotides encoding such proteins or fragments.